Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients.

Attanasio AF, Shavrikova E, Blum WF, Cromer M, Child CJ, Paskova M, Lebl J, Chipman JJ, Shalet SM

The Journal of clinical endocrinology and metabolism1 Oct 2004Cited by 64 (Europe PMC)

PMID15472176DOI10.1210/jc.2004-0551PepBankPUB-15472176

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

01HumanRandomized controlled trialEfficacy outcome
In GH-deficient patients after final height, adult-dose GH increased lean body mass by 12.7 +/- 9.4%; GH-treated patients collectively gained more than controls (P < 0.001).
In plain wordsIn GH-deficient patients after final height, adult-dose growth hormone increased lean body mass; the overall treatment comparison favored growth hormone over controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass adult dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg x d · 2 yrAs given in this study (human).
Measurements
lean body mass change
12.7%
adult-dose group (12.5 microg/kg x d), 2 yr; +/- 9.4 as written
P value
< 0.001 P value
GH-treated patients versus controls, LBM gain
Source sentences
Summary
During the 2 yr, GH-treated patients gained a significant amount of LBM compared with controls (P < 0.001), but the change with the higher pediatric dose (14.2 +/- 11.7%) was not different from that seen with the lower adult dose (12.7 +/- 9.4%; P = 0.970).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217601
02HumanRandomized controlled trialEfficacy outcome
In GH-deficient patients after final height, pediatric-dose GH increased lean body mass by 14.2 +/- 11.7%; GH-treated patients collectively gained more than controls (P < 0.001).
In plain wordsIn GH-deficient patients after final height, pediatric-dose growth hormone increased lean body mass; the overall treatment comparison favored growth hormone over controls.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass pediatric dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d · 2 yrAs given in this study (human).
Measurements
lean body mass change
14.2%
pediatric-dose group (25.0 microg/kg x d), 2 yr; +/- 11.7 as written
P value
< 0.001 P value
GH-treated patients versus controls, LBM gain
Source sentences
Summary
During the 2 yr, GH-treated patients gained a significant amount of LBM compared with controls (P < 0.001), but the change with the higher pediatric dose (14.2 +/- 11.7%) was not different from that seen with the lower adult dose (12.7 +/- 9.4%; P = 0.970).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217602
03HumanRandomized controlled trialEfficacy outcome
In GH-deficient patients after final height, lean body mass gains did not differ between pediatric and adult GH doses (P = 0.970).
In plain wordsIn GH-deficient patients after final height, lean body mass gains did not differ between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeLean body mass dose comparison
Study
n: not reported in source
Comparator
adult dose
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
lean body mass change
14.2%
pediatric dose; +/- 11.7 as written
lean body mass change
12.7%
adult dose; +/- 9.4 as written
P value
0.97 P value
pediatric versus adult dose, LBM change
Source sentences
Summary
During the 2 yr, GH-treated patients gained a significant amount of LBM compared with controls (P < 0.001), but the change with the higher pediatric dose (14.2 +/- 11.7%) was not different from that seen with the lower adult dose (12.7 +/- 9.4%; P = 0.970).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217603
04HumanRandomized controlled trialEfficacy outcome
In GH-deficient patients after final height, fat mass responses did not differ between GH doses (P = 0.950).
In plain wordsIn GH-deficient patients after final height, fat mass responses did not differ between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeFat mass dose comparison
Study
n: not reported in source
Comparator
adult dose
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
fat mass change
−7.1%
adult dose; +/- 22.8 as written
fat mass change
−6%
pediatric dose; +/- 26.6 as written
P value
0.95 P value
dose effect on fat mass change
Source sentences
Summary
Similarly, the decrease in FM was significantly (P = 0.029) influenced by treatment, but with no dose effect (adult dose, -7.1 +/- 22.8%; pediatric dose, -6.0 +/- 26.6%; P = 0.950).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217606
05HumanRandomized controlled trialEfficacy outcome
In male GH-deficient patients after final height, lean body mass gains did not differ between doses (P = 0.711).
In plain wordsIn male GH-deficient patients after final height, lean body mass gains did not differ between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeMale lean body mass dose comparison
Study
n: not reported in source
Comparator
low dose
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
lean body mass change
15.6%
males, low dose; +/- 9.8 as written
lean body mass change
14.3%
males, high dose; +/- 11.7 as written
P value
0.711 P value
males, low versus high dose, LBM
Source sentences
Summary
When the GH treatment effect was analyzed by gender, males gained 15.6 +/- 9.8% and 14.3 +/- 11.7% LBM (P = 0.711) and lost 12.4 +/- 22.2% and 11.0 +/- 27.1% FM (P = 0.921) with the low and high doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217609
06HumanRandomized controlled trialEfficacy outcome
In male GH-deficient patients after final height, fat mass changes did not differ between doses (P = 0.921).
In plain wordsIn male GH-deficient patients after final height, fat mass changes did not differ between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeMale fat mass dose comparison
Study
n: not reported in source
Comparator
low dose
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
fat mass change
−12.4%
males, low dose; reported as lost 12.4 +/- 22.2
fat mass change
−11%
males, high dose; reported as lost 11.0 +/- 27.1
P value
0.921 P value
males, low versus high dose, FM
Source sentences
Summary
When the GH treatment effect was analyzed by gender, males gained 15.6 +/- 9.8% and 14.3 +/- 11.7% LBM (P = 0.711) and lost 12.4 +/- 22.2% and 11.0 +/- 27.1% FM (P = 0.921) with the low and high doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217612
07HumanRandomized controlled trialEfficacy outcome
In female GH-deficient patients after final height, lean body mass gains did not differ between doses (P = 0.630).
In plain wordsIn female GH-deficient patients after final height, lean body mass gains did not differ between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeFemale lean body mass dose comparison
Study
n: not reported in source
Comparator
low dose
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
lean body mass change
8.3%
females, low dose; +/- 7.3 as written
lean body mass change
12.5%
females, high dose; +/- 12.8 as written
P value
0.63 P value
females, low versus high dose, LBM
Source sentences
Summary
Females gained 8.3 +/- 7.3% and 12.5 +/- 12.8% LBM with the two doses (P = 0.630), but increased their FM by 3.5 +/- 16.2% with the lower dose and lost only 1.2 +/- 23.2% FM with the higher dose (P = 0.325).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217615
08HumanRandomized controlled trialEfficacy outcome
In female GH-deficient patients after final height, fat mass changes did not differ between doses (P = 0.325).
In plain wordsIn female GH-deficient patients after final height, fat mass changes did not differ between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeFemale fat mass dose comparison
Study
n: not reported in source
Comparator
low dose
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
fat mass change
3.5%
females, low dose; increase, +/- 16.2 as written
fat mass change
−1.2%
females, high dose; reported as lost 1.2 +/- 23.2
P value
0.325 P value
females, low versus high dose, FM
Source sentences
Summary
Females gained 8.3 +/- 7.3% and 12.5 +/- 12.8% LBM with the two doses (P = 0.630), but increased their FM by 3.5 +/- 16.2% with the lower dose and lost only 1.2 +/- 23.2% FM with the higher dose (P = 0.325).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217618
09HumanRandomized controlled trialEfficacy outcome
In female GH-deficient patients after final height, pediatric-dose GH produced a higher IGF-I SD score response than adult-dose GH (P = 0.008).
In plain wordsIn female GH-deficient patients after final height, the higher growth hormone dose increased IGF-I more than the lower dose.
Peptide
HGH (somatotropin)
Outcome
IncreaseFemale IGF-I dose response
Study
n: not reported in source
Comparator
adult dose
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
P value
0.008 P value
females, pediatric versus adult dose, 2-yr IGF-I SD score response
Source sentences
Summary
A similar pattern was seen in IGF-I sd score; the 2-yr GH dose response was significantly higher with the pediatric than with the adult dose in females (P = 0.008), but not males (P = 0.790).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217619
10HumanRandomized controlled trialEfficacy outcome
In male GH-deficient patients after final height, IGF-I SD score responses did not differ significantly between doses (P = 0.790).
In plain wordsIn male GH-deficient patients after final height, IGF-I responses did not differ significantly between growth hormone doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeMale IGF-I dose response
Study
n: not reported in source
Comparator
adult dose
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25.0 microg/kg x d (pediatric dose) versus 12.5 microg/kg x d (adult dose) · 2 yrAs given in this study (human).
Measurements
P value
0.79 P value
males, pediatric versus adult dose, 2-yr IGF-I SD score response
Source sentences
Summary
A similar pattern was seen in IGF-I sd score; the 2-yr GH dose response was significantly higher with the pediatric than with the adult dose in females (P = 0.008), but not males (P = 0.790).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217620
11HumanNon-randomized trialEfficacy outcome
In GH-deficient patients after final height, adult-dose GH changed fat mass by -7.1 +/- 22.8%, with a significant overall treatment effect (P = 0.029).
In plain wordsIn GH-deficient patients after final height, adult-dose growth hormone reduced fat mass, with a significant overall treatment effect versus control.
Peptide
HGH (somatotropin)
Outcome
DecreaseFat mass adult dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg x d · 2 yrAs given in this study (human).
Measurements
fat mass change
−7.1%
adult-dose group (12.5 microg/kg x d), 2 yr; +/- 22.8 as written
P value
0.029 P value
overall treatment effect on fat mass decrease
Source sentences
Summary
Similarly, the decrease in FM was significantly (P = 0.029) influenced by treatment, but with no dose effect (adult dose, -7.1 +/- 22.8%; pediatric dose, -6.0 +/- 26.6%; P = 0.950).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217604
12HumanNon-randomized trialEfficacy outcome
In GH-deficient patients after final height, pediatric-dose GH changed fat mass by -6.0 +/- 26.6%, with a significant overall treatment effect (P = 0.029).
In plain wordsIn GH-deficient patients after final height, pediatric-dose growth hormone reduced fat mass, with a significant overall treatment effect versus control.
Peptide
HGH (somatotropin)
Outcome
DecreaseFat mass pediatric dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d · 2 yrAs given in this study (human).
Measurements
fat mass change
−6%
pediatric-dose group (25.0 microg/kg x d), 2 yr; +/- 26.6 as written
P value
0.029 P value
overall treatment effect on fat mass decrease
Source sentences
Summary
Similarly, the decrease in FM was significantly (P = 0.029) influenced by treatment, but with no dose effect (adult dose, -7.1 +/- 22.8%; pediatric dose, -6.0 +/- 26.6%; P = 0.950).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217605
13HumanNon-randomized trialEfficacy outcome
In male GH-deficient patients after final height, low-dose GH increased lean body mass by 15.6 +/- 9.8%.
In plain wordsIn male GH-deficient patients after final height, lean body mass increased during low-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale lean body mass low dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg x d · 2 yrAs given in this study (human).
Measurements
lean body mass change
15.6%
males, low dose (12.5 microg/kg x d); +/- 9.8 as written
Source sentences
Summary
When the GH treatment effect was analyzed by gender, males gained 15.6 +/- 9.8% and 14.3 +/- 11.7% LBM (P = 0.711) and lost 12.4 +/- 22.2% and 11.0 +/- 27.1% FM (P = 0.921) with the low and high doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217607
14HumanNon-randomized trialEfficacy outcome
In male GH-deficient patients after final height, high-dose GH increased lean body mass by 14.3 +/- 11.7%.
In plain wordsIn male GH-deficient patients after final height, lean body mass increased during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseMale lean body mass high dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d · 2 yrAs given in this study (human).
Measurements
lean body mass change
14.3%
males, high dose (25.0 microg/kg x d); +/- 11.7 as written
Source sentences
Summary
When the GH treatment effect was analyzed by gender, males gained 15.6 +/- 9.8% and 14.3 +/- 11.7% LBM (P = 0.711) and lost 12.4 +/- 22.2% and 11.0 +/- 27.1% FM (P = 0.921) with the low and high doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217608
15HumanNon-randomized trialEfficacy outcome
In male GH-deficient patients after final height, low-dose GH reduced fat mass by 12.4 +/- 22.2%.
In plain wordsIn male GH-deficient patients after final height, fat mass decreased during low-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseMale fat mass low dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg x d · 2 yrAs given in this study (human).
Measurements
fat mass change
−12.4%
males, low dose (12.5 microg/kg x d); reported as lost 12.4 +/- 22.2
Source sentences
Summary
When the GH treatment effect was analyzed by gender, males gained 15.6 +/- 9.8% and 14.3 +/- 11.7% LBM (P = 0.711) and lost 12.4 +/- 22.2% and 11.0 +/- 27.1% FM (P = 0.921) with the low and high doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217610
16HumanNon-randomized trialEfficacy outcome
In male GH-deficient patients after final height, high-dose GH reduced fat mass by 11.0 +/- 27.1%.
In plain wordsIn male GH-deficient patients after final height, fat mass decreased during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseMale fat mass high dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d · 2 yrAs given in this study (human).
Measurements
fat mass change
−11%
males, high dose (25.0 microg/kg x d); reported as lost 11.0 +/- 27.1
Source sentences
Summary
When the GH treatment effect was analyzed by gender, males gained 15.6 +/- 9.8% and 14.3 +/- 11.7% LBM (P = 0.711) and lost 12.4 +/- 22.2% and 11.0 +/- 27.1% FM (P = 0.921) with the low and high doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217611
17HumanNon-randomized trialEfficacy outcome
In female GH-deficient patients after final height, low-dose GH increased lean body mass by 8.3 +/- 7.3%.
In plain wordsIn female GH-deficient patients after final height, lean body mass increased during low-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFemale lean body mass low dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg x d · 2 yrAs given in this study (human).
Measurements
lean body mass change
8.3%
females, low dose (12.5 microg/kg x d); +/- 7.3 as written
Source sentences
Summary
Females gained 8.3 +/- 7.3% and 12.5 +/- 12.8% LBM with the two doses (P = 0.630), but increased their FM by 3.5 +/- 16.2% with the lower dose and lost only 1.2 +/- 23.2% FM with the higher dose (P = 0.325).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217613
18HumanNon-randomized trialEfficacy outcome
In female GH-deficient patients after final height, high-dose GH increased lean body mass by 12.5 +/- 12.8%.
In plain wordsIn female GH-deficient patients after final height, lean body mass increased during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFemale lean body mass high dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d · 2 yrAs given in this study (human).
Measurements
lean body mass change
12.5%
females, high dose (25.0 microg/kg x d); +/- 12.8 as written
Source sentences
Summary
Females gained 8.3 +/- 7.3% and 12.5 +/- 12.8% LBM with the two doses (P = 0.630), but increased their FM by 3.5 +/- 16.2% with the lower dose and lost only 1.2 +/- 23.2% FM with the higher dose (P = 0.325).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217614
19HumanNon-randomized trialEfficacy outcome
In female GH-deficient patients after final height, low-dose GH increased fat mass by 3.5 +/- 16.2%.
In plain wordsIn female GH-deficient patients after final height, fat mass increased during low-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFemale fat mass low dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg x d · 2 yrAs given in this study (human).
Measurements
fat mass change
3.5%
females, low dose (12.5 microg/kg x d); increase, +/- 16.2 as written
Source sentences
Summary
Females gained 8.3 +/- 7.3% and 12.5 +/- 12.8% LBM with the two doses (P = 0.630), but increased their FM by 3.5 +/- 16.2% with the lower dose and lost only 1.2 +/- 23.2% FM with the higher dose (P = 0.325).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217616
20HumanNon-randomized trialEfficacy outcome
In female GH-deficient patients after final height, high-dose GH reduced fat mass by 1.2 +/- 23.2%.
In plain wordsIn female GH-deficient patients after final height, fat mass decreased during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseFemale fat mass high dose
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
25.0 microg/kg x d · 2 yrAs given in this study (human).
Measurements
fat mass change
−1.2%
females, high dose (25.0 microg/kg x d); reported as lost 1.2 +/- 23.2
Source sentences
Summary
Females gained 8.3 +/- 7.3% and 12.5 +/- 12.8% LBM with the two doses (P = 0.630), but increased their FM by 3.5 +/- 16.2% with the lower dose and lost only 1.2 +/- 23.2% FM with the higher dose (P = 0.325).
2 context sentences(design, population, supporting numbers)
Summary · context
To test the hypothesis that continued GH therapy after final height is necessary to attain adult body composition, we performed a prospective, multinational, randomized, controlled, 2-yr study in patients who completed pediatric GH treatment at final height.
Summary · context
Patients were randomized to GH at 25.0 microg/kg x d (pediatric dose; n = 58) or 12.5 microg/kg x d (adult dose; n = 59) or no GH treatment (control; n = 32).
Report a problemFND-1547217617

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.